Child Psychiatry Fellowship
Columbia University
New York, NY
Psychiatry Residency
New England Medical Center/Tufts University School of Medicine
Boston, MA
Areas of Interest
Child psychiatry
Pediatric mood disorders
Pediatric psychopharmacology
Publications
Compton SN, Walkup JT, Albano AM, Piacentini JC, Birmaher B, Sherrill JT, Ginsburg GS, Rynn MA, McCracken JT, Waslick BD, Iyengar S, Kendall PC, March JS. Child/Adolescent Anxiety Multimodal Study (CAMS): Rationale, design and methods. Child Adolesc Psychiatry Ment Health 2010;4:Article 1.
Vitiello B, Waslick B. Pharmacotherapy for children and adolescent with anxiety disorders. Psychiatr Ann 2010;40:185-191.
Waslick BD, Brooks B, Burns J, Sarvet B. Depression: an Overview, in Handbook of Adolescent Depression in Primary Care, edited by Jensen P, Zuckerbrot R, Cheung A. In press
Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, Iyengar S, March JS, Kendall PC. Cognitive behavioral therapy, Sertraline, or a combination in childhood anxiety. N Eng J Med, 2008;359:2753-2766
Emslie GJ, Waslick BD, Weller EB et al. Antidepressant management in the context of suicidal ideation. JAACAP, 2007; 46:1222-1225
Waslick BD. Benefits and harms of pediatric antidepressant medications (letter). JAMA, 2007; 298: 626
Zuckerbrot A, Cheung A, Jensen P, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): I. Identification, Assessment, and InitialManagement. Pediatrics, Nov 2007; 120: e1299 - e1312
Cheung A, Zuckerbrot R, Jensen P, et al. Guidelines for adolescent depression in primary care (GLAD-PC): II. Treatment and Ongoing Management. Pediatrics. 2007120: e1313 - e1326
TADS Cooperative Group. The Treatment for Adolescents with Depression Study (TADS): Long-Term Effectiveness and Safety Outcomes. Archives of GeneralPsychiatry, 2007; 64: 1132 – 1143
Kennard BD, Silva S, Vitiello B et al. Remission and residual symptoms after acute treatment of adolescents with major depressive disorder. JAACAP, 2006; 45:1404-1411
Kratochvil C, Emslie G, Silva S et al. Acute time to response in the treatment for adolescents with depression study (TADS). JAACAP, 2006; 45:1412-1418
Vitiello B, Rhode P, Silva S, Wells K, Casat C, Waslick BD, Simmons A et al. Functioning and quality of life in the treatment for adolescents with depression study (TADS). JAACAP, 2006; 45:1419-1428
Curry JF, Rohde P, Silva S, Vitiello B, Simons A, et al. Predictors and moderators of acute outcome in the treatment for adolescents with depression study (TADS). JAACAP, 2006; 45:1427-1439
Emslie G, Kratochvil CJ, Vitiello B, March J, Weller E, Waslick BD, Casat C, et al. Treatment for adolescents with depression (TADS): safety results. JAACAP, 2006;45:1440-1455
Waslick BD Oxcarbazepine and pediatric bipolar disorder (letter). Am J Psychiatry 2006; 163: 2195
Bolfek A, Jankowski JJ, Waslick BD, Summergrad P. Adolescent psychopharmacology: drugs for mood disorders. Adolescent Medicine Clinics. 2006; 17(3):789-808
Waslick BD, Psychopharmacology interventions for pediatric anxiety disorders: a research update. Child and Adolescent Psychiatry Clinics of North America. 2006
Waslick BD, Greenhill LL, Attention-deficit hyperactivity disorder. In M. Dulcan, Essentials of Child and Adolescent Psychiatry, American Psychiatric Press, Inc. 2006
Kratochvil CJ, Vitiello B, Walkup J, Emslie G, Waslick BD, Weller E, Burke WJ, March J, SSRIs in pediatric depression: is the balance between benefits and harms favorable? Journal of Child and Adolescent Psychopharmacology. 2006
Grants
2006-2010, Site Principal Investigator, An Open-label, Prospective Cohort Study of Antidepressants in Children and Adolescents with Anxiety Disorders, Depressive Disorders, Eating Disorder, or Obsessive-Compulsive Disorder, Duke University
2007-2010, Principal Investigator, A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible-Dose Study of the Safety and Efficacy of Emsam® in Adolescents with Major Depression, Somerset Pharmaceuticals
2008-2011, Principal Investigator, The Evaluation of LAMICTAL as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, GlaxoSmithKline
2009, Principal Investigator, A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination with Psychostimulants in Children and Adolescents Aged 6-17 with a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD), Shire Development, Inc
